A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2016

At a glance

  • Drugs Forigerimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms Celestial 47
  • Sponsors Cephalon
  • Most Recent Events

    • 20 Nov 2012 Results have been presented at the 2012 American College of Rheumatology Meeting (ACR-2012) according to an ImmuPharma media release.
    • 14 Nov 2012 Primary endpoint 'Systemic-Lupus-Erythematosus-Responder-Index' has not been met.
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top